[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100471888":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":24,"responsibleParty":44,"collaborators":7,"id":46,"slug":7,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":7,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":7,"targetDuration":7,"studyType":55,"phases":7,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":27,"whyStopped":7,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":7,"completionDateStruct":7,"leadSponsor":68,"locationsCount":69},{"fullName":5,"class":6},"DBV Technologies","INDUSTRY",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"COMBINATION_PRODUCT","DBV712 250 mcg","Daily epicutaneous delivery.",[14],"Viaskin® Peanut",[16,22],{"name":17,"role":18,"phone":19,"phoneExt":20,"email":21},"Anne B Cropp, Pharm. D.","CONTACT","1-888-441-793","125","DBV712.eap@earlyaccesscare.com",{"name":23,"role":18,"phone":19,"phoneExt":20,"email":21},"Laurie Reynolds, BS",[25],{"facility":26,"status":27,"city":28,"state":29,"zip":30,"country":31,"cosmosGeoPoint":32,"geoPoint":37,"contacts":38},"Early Access Care, LLC","AVAILABLE","Madison","Connecticut","06443","United States",{"type":33,"coordinates":34},"Point",[35,36],-72.59843,41.27954,{"lat":36,"lon":35},[39,41],{"name":17,"role":18,"phone":40,"phoneExt":20,"email":21},"888-441-7938",{"name":42,"role":18,"phone":43,"phoneExt":20,"email":21},"Laurie Reynolds, 06443","1-888-441-7938",{"type":45,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100471888",false,"NCT05424731","Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children","Viaskin® Peanut (DBV712) Compassionate Use in Peanut-allergic Children Previously Enrolled in a DBV712 Clinical Study","Inclusion Criteria:\n\n* Participation is by invitation, limited to individuals completing clinical study V712-303 (PEOPLE), previous Expanded Access Program or a DBV clinical study initiated after 31-Jan-2022\n* Male and females; ages ≥ 2 years old at Visit 1 or current or prior studies.\n* Negative urine pregnancy test for female participants of childbearing potential.\n\nExclusion Criteria:\n\n* Early withdrawal from a DBV712 clinical study.\n* History of non-compliance during the primary clinical study or unable to follow the protocol requirements.\n* Generalized dermatologic disease extending widely on the skin.\n* History of intolerance or who developed hypersensitivity to excipients of the DBV712 patches.","ALL","2 Years","17 Years","EXPANDED_ACCESS","This is an open label expanded access program for male and female patients 2 years or older, to provide continued desensitization treatment with DBV712 250 mcg.",[58],"Peanut Allergy",[60,61,62,63],"EPIT","Epicutaneous","Immunotherapy","Viaskin","2026-01-14",{"date":66,"type":67},"2026-01-15","ACTUAL",{"name":5,"class":6},1]